FDA Commissioner Robert Califf has two plans for what he wants to achieve during his tenure. One is long-term. The other ends in early 2017.
Donald Trump and Hillary Clinton offer clear contrasts on the issues of the Affordable Care Act, entitlement reform, and drug pricing.
Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
That change is coming about in the wake of a string of First Amendment-based losses for the FDA in federal courts around the country.
We need to consider that not every expenditure is beneficial to patients: perhaps that Super Bowl commercial or that sales meeting in Maui may not be in their best interest.
The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.
It is worth noting that the FDA sent only nine warning letters last year, all focused on well-recognized violations, such as minimization of risk information and unsubstantiated claims.
In a town where the main business is politics, the election of a new president heightens the intensity.
Anyone who thinks that the argument over off-label communications is just about marketing and sales is looking at the issue through very narrow blinders
Would you expect that patient power exerted through social media might shake the job of a high-level FDA center director?
When will the pharma industry resume working with Congress on drug safety?
Passing the 21st Century Cures Act was a bipartisan success due to open lines of dialogue among stakeholders
Perhaps the best testament to Commissioner Hamburg's tenure is that crises were uniformly handled responsibly
After a decade spent stalling, denying and attacking critics, the University of Minnesota has finally admitted some complicity in the death of a patient during a clinical drug trial.
The FDA has to respect First Amendment limitations regulating scientific communication
The FDA must address its policies to accommodate the new medical and media environment
With POC on the march, the FDA will have to stretch its monitoring efforts to keep up
One issue lurking for marketers is the potential elimination of the tax exemption for advertising
I come not to bury government but to praise it—at least the singular agency I know best: FDA
Demonizing new treatments distracts from the real problem: policies that focus on the near-term
A charge of sexism against the FDA clouds the views surrounding a drug's application
Problems and changes have set ablaze criticism over the Sunshine Act's implementation
What happens when it's the FDA—not a medical marketer—that is doing the overstating?
A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive
A Manhattan Institute analysis says that helping underperforming FDA drug review divisions match the output of high-performing divisions could cut development costs and speed approval of new treatments.
Nineteen Republicans on the House Energy and Commerce Committee want FDA commissioner Margaret Hamburg to explain the role the American Association for Justice (trial lawyers) played in drafting proposed changes to generic drug labeling.
FDA has insisted that its antique regulations can address every new promotional challenge
Former Speaker of the House and presidential candidate Newt Gingrich has declared that it's time to replace FDA
The more clarity that FDA provides, the more confident companies can be in their medical communications
US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro
FDA's Office of Prescription Drug Promotion (OPDP) plans to research the effects that could follow changing the risk information the agency requires to be included in such direct-to-consumer ads.
We need for pharmaceutical companies to come forward and make the pledge to stop hiding data
California Democrat Henry Waxman, one of the strongest FDA overseers and drug industry critics on Capitol Hill, will step down when the House of Representatives adjourns for the mid-term elections
FDA's drug center says it has been so overwhelmed with industry's response to its new Breakthrough Therapy program that it is becoming difficult to promise an "all hands" commitment.
FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals
The US Supreme Court has declined, without comment, to hear a closely watched appeal by former InterMune CEO Scott Harkonen on whether someone can be prosecuted for speaking truthfully about a drug.
Public Citizen has written FDA asking it to stop making "misleading" statements about pharmacy compounding
It's fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes
A McKinsey Center for Government analysis shows that in the period 2001-2010, FDA approved 88% of NDAs and BLAs that were supported by advisory committees and did not approve 86% of those not endorsed by the committees.
Under a $4-million contract from FDA, RTI International researchers will look at consumers' responses to risk, benefit and cost information in direct-to-consumer prescription drug ads
Keeping up with quality programs often feels like a safari in a jungle of government paperwork
Under pressure from Public Citizen and FDA, Dermatologic and Ophthalmic Drugs Advisory Committee chair Lynn Drake withdrew her acceptance of an invitation to provide a presentation to industry on winning a favorable panel endorsement.
Two researchers say that expedited review of new drugs may have exposed some patients to safety risks that had not been well characterized.
Could PAG change the FDA inspection paradigm from honest, objective assessments to faster, easier ones?
The Federal Trade Commission has announced a Dec. 4 workshop to "examine the practice of blending advertisements with news, entertainment, and other content in digital media."
FDA's director of drugs, Janet Woodcock, said in September that she will personally direct the agency's latest push to advance pharmaceutical quality.
By opposing making clinical trial data public, Pharma is once again swimming against the current
FDA stakeholders in industry and academia told the agency in August that they're concerned about its newest initiative to make clinical trial data more publicly available
A study of government drug review advisory panels suggests that those with members who have financial ties to the drug industry recommended expansion of labeled disease indications for the drugs examined
- Guidemark Health merges with three companies to form new agency
- Five things for pharma marketers to know: Monday, October 17, 2016
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- Five things for pharma marketers to know: Friday, October 21, 2016
- Trump or Clinton? Either May Lead to Better Mental Healthcare
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Why Excedrin embraced the headache of a contentious election season
- StartUp Health reports more global deals, uptick in pharma investment in digital health